Chief Medical Officer Birgitte Volck to leave Sobi

To join GlaxoSmithKline as Head of R&D Rare Diseases

Birgitte Volck, Senior Vice President of Development and Chief Medical Officer (CMO) at Swedish Orphan Biovitrum (Sobi) is leaving the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases. Volck will work through a six-month notice period before leaving the company.

'We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team,' said Geoffrey McDonough, President and CEO of Sobi.

Volck joined Sobi in 2012 and has been instrumental in advancing the firm's late stage development projects and in bringing new treatment options to people with rare diseases, he added.

You may also like

Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Regulatory

GSK's respiratory syncytial virus vaccine receives approval

The MHRA has authorised has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for immunisation for LRTD in adults 60 years or older
Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Ingredients

Therapeutic: bepirovirsen for chronic hepatitis B

The hepatitis B virus causes both acute and chronic disease. Chronic hepatitis B can progress to complications including cirrhosis and liver cancer
Finance

Sareum notes completion of Sierra Oncology’s acquisition by GSK

Sareum Holdings, the specialist drug development company, notes that GSK has completed its acquisition of Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), for $1.9 billion in cash
Subscribe now